The company also received the European regulatory nod for its BrainSense Electrode Identifier (EI). Following approval, Dr. Martijn Beudel completed the first programming of the technology in Amsterdam. The medtech giant says the approval and first-in-Europe patient programming highlight significant advancements in personalized DBS therapy for people with Parkinson’s.

BrainSense aDBS, delivered through the Medtronic Percept neurostimulator, provides real-time, adaptive therapy. It dynamically adjusts stimulation based on each person’s unique brain activity, both in clinical settings and daily life. The BrainSense EI technology can improve DBS programming by ensuring optimal initial contact selection in less time.